Key Insights

Highlights

Success Rate

89% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

5.4%

2 terminated out of 37 trials

Success Rate

89.5%

+3.0% vs benchmark

Late-Stage Pipeline

5%

2 trials in Phase 3/4

Results Transparency

18%

3 of 17 completed with results

Key Signals

3 with results89% success

Data Visualizations

Phase Distribution

23Total
Not Applicable (13)
Early P 1 (1)
P 1 (7)
P 4 (2)

Trial Status

Completed17
Recruiting5
Unknown5
Suspended3
Withdrawn3
Not Yet Recruiting2

Trial Success Rate

89.5%

Benchmark: 86.5%

Based on 17 completed trials

Clinical Trials (37)

Showing 20 of 20 trials
NCT07566806Not ApplicableRecruiting

Evaluation of the Clinical Efficacy and Mechanisms of Cord Plasma Eye Drops in the Treatment of Neuropathic Corneal Pain

NCT05694247Not ApplicableSuspendedPrimary

Study to Evaluate the Clinical Safety and Performance of the CorNeat KPro for Treatment of Corneal Blindness

NCT06101017CompletedPrimary

Developing a Nationwide Registry to Track Longitudinal Clinical Outcomes of Corneal Surgery and Disease

NCT05758753Not ApplicableSuspendedPrimary

QST for Corneal Nerve Function

NCT05653921Suspended

Prospective Study to Validate the Imaging Biomarker for NCP (R33)

NCT06211218Recruiting

Artificial Intelligence for Screening of Multiple Corneal Diseases

NCT04485858Not ApplicableTerminatedPrimary

First in Human (FIH) Study to Assess Safety and Efficacy of the CorNeat KPro for the Treatment of Corneal Blindness

NCT06294015Phase 4Not Yet Recruiting

Efficacy of 20% Autologous Serum Drops in the Treatment of Corneal Epitheliopathy Associated With Antihypertensive Glaucoma Drops.

NCT02386774Not ApplicableCompletedPrimary

Innovative Imaging of the Conjunctiva, Cornea, and Ocular Adnexa

NCT06160960Unknown

Influence of Pupillary Behavior During Eye Surgery on Morphological and Functional Outcome

NCT05280275Phase 1Recruiting

A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible

NCT05573802Phase 1Recruiting

A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma

NCT03990506Not ApplicableCompleted

Photorefractive Intrastromal Crosslinking (PiXL) for the Treatment of Progressive Keratoconus

NCT04318132Not ApplicableCompleted

Agreement and Precision Study of the Nidek Mirante

NCT04251143Recruiting

Dresden Corneal Disease and Treatment Study

NCT05700864Phase 1WithdrawnPrimary

NGF Treatment for Patients With Neuropathic Corneal Pain

NCT05581875Phase 1Not Yet Recruiting

A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory

NCT04475900Completed

Computer-aided Diagnosis of Ocular Diseases Based on Corneal Biomechanics

NCT05447845Unknown

Rapid Computerized Visual Acuity Test

NCT05114928Completed

Correlation Between Q-value Changes and Progression of Pediatric Keratoconus.

Scroll to load more

Research Network

Activity Timeline